These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

935 related items for PubMed ID: 27746094

  • 1. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
    Kondo N, Murakami Y, Uemura K, Nakagawa N, Takahashi S, Ohge H, Sueda T.
    Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
    [Abstract] [Full Text] [Related]

  • 2. Increased levels of both carbohydrate antigen 19-9 and duke pancreatic monoclonal antigen type 2 reflect postoperative prognosis in patients with pancreatic carcinoma.
    Shibata K, Iwaki K, Kai S, Ohta M, Kitano S.
    Pancreas; 2009 Aug; 38(6):619-24. PubMed ID: 19436235
    [Abstract] [Full Text] [Related]

  • 3. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
    Distler M, Pilarsky E, Kersting S, Grützmann R.
    Int J Surg; 2013 Aug; 11(10):1067-72. PubMed ID: 24161419
    [Abstract] [Full Text] [Related]

  • 4. Clinical significance of serum carbohydrate antigen 19.9 and duke pancreatic monoclonal antigen type 2 for the prediction of hematogenous metastases in patients with pancreatic ducal adenocarcinoma.
    Kurahara H, Maemura K, Mataki Y, Sakoda M, Iino S, Arigami T, Mori S, Ueno S, Shinchi H, Takao S, Natsugoe S.
    Pancreatology; 2016 Aug; 16(6):1051-1056. PubMed ID: 27693096
    [Abstract] [Full Text] [Related]

  • 5. Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer.
    Asaoka T, Miyamoto A, Maeda S, Tsujie M, Hama N, Yamamoto K, Miyake M, Haraguchi N, Nishikawa K, Hirao M, Ikeda M, Sekimoto M, Nakamori S.
    Pancreatology; 2016 Aug; 16(3):434-40. PubMed ID: 26852169
    [Abstract] [Full Text] [Related]

  • 6. Doublecortin and CaM kinase-like-1 as an independent prognostic factor in patients with resected pancreatic carcinoma.
    Nishio K, Kimura K, Amano R, Nakata B, Yamazoe S, Ohira G, Miura K, Kametani N, Tanaka H, Muguruma K, Hirakawa K, Ohira M.
    World J Gastroenterol; 2017 Aug 21; 23(31):5764-5772. PubMed ID: 28883702
    [Abstract] [Full Text] [Related]

  • 7. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
    Xu HX, Liu L, Xiang JF, Wang WQ, Qi ZH, Wu CT, Liu C, Long J, Xu J, Ni QX, Yu XJ.
    Surgery; 2017 Feb 21; 161(2):373-384. PubMed ID: 27838102
    [Abstract] [Full Text] [Related]

  • 8. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
    Dong Q, Yang XH, Zhang Y, Jing W, Zheng LQ, Liu YP, Qu XJ.
    World J Surg Oncol; 2014 Jun 02; 12():171. PubMed ID: 24890327
    [Abstract] [Full Text] [Related]

  • 9. Normalization of CA19-9 following resection for pancreatic ductal adenocarcinoma is not tantamount to being cured?
    Chen T, Zhang MG, Yu XJ, Liu L.
    Asian Pac J Cancer Prev; 2015 Jun 02; 16(2):661-6. PubMed ID: 25684504
    [Abstract] [Full Text] [Related]

  • 10. Clinical Utility of the Combined Use of CA19-9 and DUPAN-2 in Pancreatic Adenocarcinoma.
    Sumiyoshi T, Uemura K, Shintakuya R, Okada K, Baba K, Harada T, Serikawa M, Ishii Y, Nakamura S, Arihiro K, Murakami Y, Takahashi S.
    Ann Surg Oncol; 2024 Jul 02; 31(7):4665-4672. PubMed ID: 38652196
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Long-term survival after resection of pancreatic cancer: a single-center retrospective analysis.
    Yamamoto T, Yagi S, Kinoshita H, Sakamoto Y, Okada K, Uryuhara K, Morimoto T, Kaihara S, Hosotani R.
    World J Gastroenterol; 2015 Jan 07; 21(1):262-8. PubMed ID: 25574100
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of preoperative prognostic factors in patients with resectable pancreatic ductal adenocarcinoma.
    Izumo W, Higuchi R, Furukawa T, Yazawa T, Uemura S, Shiihara M, Yamamoto M.
    Scand J Gastroenterol; 2019 Jun 07; 54(6):780-786. PubMed ID: 31180790
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time.
    Rieser CJ, Zenati M, Hamad A, Al Abbas AI, Bahary N, Zureikat AH, Zeh HJ, Hogg ME.
    Ann Surg Oncol; 2018 Nov 07; 25(12):3483-3491. PubMed ID: 29786131
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A new preoperative prognostic scoring system to predict prognosis in patients with locally advanced pancreatic body cancer who undergo distal pancreatectomy with en bloc celiac axis resection: a retrospective cohort study.
    Miura T, Hirano S, Nakamura T, Tanaka E, Shichinohe T, Tsuchikawa T, Kato K, Matsumoto J, Kondo S.
    Surgery; 2014 Mar 07; 155(3):457-67. PubMed ID: 24462074
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.